Psoriasis, Skin Diseases
Conditions
Brief summary
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.
Detailed description
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis. The study has 2 parts: first part (randomized double-blind) and second part (open).
Interventions
DRUGAK111
AK111 regimen 1-subcutaneous injection,until week 24.
Sponsors
Akeso
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female subjects aged ≥18 years old. 2. Subjects with moderate to severe plaque psoriasis with or without psoriatic arthritis. 3. At screening and baseline, PASI score ≥ 12, BSA ≥ 10%, sPGA ≥ 3. 4. Suitable for systematic therapy assessed by investigators. 5. Subjects who are women of childbearing potential must be practicing an adequate, medically acceptable method of birth control during the study and for at least 6 months after the last investigational drug administration.
Exclusion criteria
1. Types of psoriasis other than chronic plaque-type psoriasis. 2. Drug-induced psoriasis. 3. Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol. 4. Positive results of confirmatory test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis. 5. History of repeated chronic infection, had any serious infection or systemic infection within 2 months before screening. 6. Progressive or uncontrolled symptoms or signs of circulatory, respiratory, digestive, neuropsychiatric or psychological,hematological, endocrine and other systems before randomization. 7. History of malignant tumour within 5 years before screening. 8. Previous or current autoimmune diseases. 9. Allergic to any component of the investigational drug, or have had severe allergic reactions to monoclonal antibodies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of subjects who achieved at least 75% reduction in Psoriasis Area Severity Index （PASI）score from baseline (PASI 75) and the percentage of subjects with sPGA 0/1 at week 16. | at week 16 | PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%),and severity is estimated by clinical signs, erythema, induration and desquamation: scale 0 (none) to 4 (maximum).Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3,legs: 0.4).PASI 50, PASI75 and PASI 90 were defined as participants achieving \>= 50%, \>= 75% or \>= 90% improvement from baseline, respectively.The sPGA is an instrument providing a subjective evaluation of the overall severity of psoriasis, based on severity of induration, scaling, and erythema. The scores are: 0 = clear; 1 = minimal; 2 = mild; 3 = moderate; 4 = marked; 5 =severe. |
Secondary
| Measure | Time frame |
|---|---|
| The percentage of subjects who achieved at least 90% reduction in PASI score from baseline (PASI 90). | at week 16 |
Countries
China
Outcome results
None listed